ALS, MND, amyotrophic lateral sclerosis
Conditions
Interventions
None listed
Sponsors
University Medical Center Utrecht, the Netherlands
Vesalius Research Center, VIB, Leuven, Belgium
University Hospital Jena, Germany
Eligibility
Inclusion criteria
Inclusion criteria: All patients with ALS.
Exclusion criteria
Exclusion criteria: N/A
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Report on key molecular drivers in transcriptomic data related to disease progression (month 35); 2. Report on key molecular drivers in methylation data related to disease progression (month 35); 3. Report on key molecular drivers in proteomic data related to disease progression (month 35); 4. Report on longitudinal MRI and MUNIX changes related to disease progression (month 35). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Tender document for appropriate SMEs that describes most promising therapeutic targets, based on differential co-expression, co-methylation and co-translation reports; 2. Tender document for appropriate SMEs that describes most promising molecular disease progression markers based on those markers that best discriminate between fast and slow progressors. | — |
Contacts
Public ContactPetra Berk
UMC Utrecht Dept Neurology, G03.232 Heidelberglaan 100
Outcome results
None listed